Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from EQS Group

19:22 EDT 15th July 2018 | BioPortfolio

Here are the most relevant search results for "EQS Group" found in our extensive news archives from over 250 global news sources.

More Information about EQS Group on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about EQS Group for you to read. Along with our medical data and news we also list EQS Group Clinical Trials, which are updated daily. BioPortfolio also has a large database of EQS Group Companies for you to search.

Showing News Articles 1–25 of 619 from EQS Group

Friday 13th July 2018

Drägerwerk AG & Co. KGaA: preliminary result for the first half year

Drägerwerk AG & Co. KGaA / Key word(s): Preliminary Results Drägerwerk AG & Co. KGaA: preliminary result for the first half year 13-Jul-2018 / 17:33 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Based on pre...

Medios AG: Successful Annual General Meeting 2018 - High approval of all agenda items

DGAP-News: Medios AG / Key word(s): AGM/EGM 13.07.2018 / 16:54 The issuer is solely responsible for the content of this announcement. Corporate News   Medios AG: Successful Annual General Meeting 2018 - High approval of all agenda items Berlin, 13 July 2018 - Medios AG ('Medios'), one of the leading Specialty Pharma companies in Germany, has successfully held its 2018 Annual Gene...

MPH Health Care AG: Significant dividend increase from 0.12 EUR to 0.20 EUR per share approved

DGAP-News: MPH Health Care AG / Key word(s): Final Results/Sustainability 13.07.2018 / 16:03 The issuer is solely responsible for the content of this announcement. MPH Health Care AG: Significant dividend increase from 0.12 EUR to 0.20 EUR per share approved - Dividend yield at 4 % - Annual general meeting approves all agenda items Berlin, July 13, 2018: The shareholders of MPH Healt...

Probiodrug (PBD-NA): Positive read-across from BAN2401 Phase II data

goetzpartners securities Limited 13-Jul-2018 / 10:27 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clien...

Hardman & Co Research: Allergy Therapeutics (AGY): Steady performance in a tough market

Hardman & Co Research 13-Jul-2018 / 09:40 GMT/BST Hardman & Co Research: Steady performance in a tough market AGY is a long-established specialist in the prevention, diagnosis, and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in the EU only on a 'Named Patient' basis. The Phas...

Biofrontera AG: Biofrontera AG announces results of its Annual General Meeting

DGAP-News: Biofrontera AG / Key word(s): AGM/EGM 13.07.2018 / 10:40 The issuer is solely responsible for the content of this announcement. Biofrontera AG announces results of its Annual General Meeting Leverkusen, Germany, July 13, 2018 -Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced the voting results of its an...

UMS United Medical Systems International AG: UMS AG Reports on Financial Statements at April 30, 2018

DGAP-News: UMS United Medical Systems International AG / Key word(s): Final Results/Miscellaneous 13.07.2018 / 10:00 The issuer is solely responsible for the content of this announcement. UMS AG Reports on Financial Statements at April 30, 2018 Hamburg, July 13, 2018. UMS United Medical Systems International AG i.L. (UMS, ISIN DE 0005493654 / WKN 549365) has reported on the financial s...

Thursday 12th July 2018

STADA Arzneimittel AG: Xbrane and STADA enter into a co-development agreement for Xlucane

DGAP-News: STADA Arzneimittel AG / Key word(s): Alliance 12.07.2018 / 17:00 The issuer is solely responsible for the content of this announcement. Bad Vilbel, July 12, 2018 - Xbrane Biopharma AB ("Xbrane") and STADA Arzneimittel AG ("STADA") have entered into a co-development agreement for Xlucane, a Lucentis(R) (ranibizumab) biosimilar. About the agreement The collaboration between Xb...

Biofrontera AG: Biofrontera AG subsidiary files suit against DUSA Pharmaceuticals, Inc

DGAP-News: Biofrontera AG / Key word(s): Legal Matter 12.07.2018 / 13:30 The issuer is solely responsible for the content of this announcement. Biofrontera AG subsidiary files suit against DUSA Pharmaceuticals, Inc. Leverkusen, Germany, July 12, 2018 - Biofrontera Inc. ("Biofrontera"), a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), announced ...

Mauna Kea Technologies SA (MKEA-FR): Optical biopsies for increased diagnostic accuracy

goetzpartners securities Limited 12-Jul-2018 / 10:38 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clien...

Heidelberg Pharma reports on first half-year

DGAP-News: Heidelberg Pharma AG / Key word(s): Half Year Results 12.07.2018 / 07:06 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma reports on first half-year - Exclusive ATAC research collaboration with Magenta creates new options in oncology and other indications - Patent-related license agreement for potential biomarker signed...

Wednesday 11th July 2018

Gerresheimer acquires Sensile Medical / irrespective of that, increased growth and improved profitability expected mid-term due to two new major orders with temporarily higher capex / organic revenue guidance 2018 narrowed to upper end of range

Gerresheimer AG / Key word(s): Mergers & Acquisitions Gerresheimer acquires Sensile Medical / irrespective of that, increased growth and improved profitability expected mid-term due to two new major orders with temporarily higher capex / organic revenue guidance 2018 narrowed to upper end of range 11-Jul-2018 / 20:17 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of th...

STADA Arzneimittel AG: Announcement of the results of the Tender Offer regarding the STADA-Bond 2015/2022:

DGAP-News: STADA Arzneimittel AG / Key word(s): Bond 11.07.2018 / 17:15 The issuer is solely responsible for the content of this announcement. Investor News NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES. Bad Vilbel, 11 July, 2018 - STADA Arzneimittel Aktiengesellschaft (the "Offeror") with its registered office at Stadastraße 2-18...

Immutep Limited (IMM-AU): Targeting the LAG-3 immune checkpoint

goetzpartners securities Limited 11-Jul-2018 / 10:24 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clien...

Rapid Nutrition Secures Distribution Deal in Sri Lanka

EQS Group-News: Rapid Nutrition PLC / Key word(s): Miscellaneous 11.07.2018 / 08:00 Rapid Nutrition Secures Distribution Deal in Sri Lanka ("Rapid Nutrition" or "the Company")   London July 11, 2018: The board is pleased to announce Rapid Nutrition has continued to expand in the rapidly growing Asia market securing a distribution agreement with Schering Life Sciences to market and...

Tuesday 10th July 2018

MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn's Disease (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study/Miscellaneous 10.07.2018 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, July 10, 2018 MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn's Disease MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NAS...

Biofrontera AG: Phase 1 of Collaboration between Biofrontera and Maruho completed

DGAP-News: Biofrontera AG / Key word(s): Alliance/Contract 10.07.2018 / 15:10 The issuer is solely responsible for the content of this announcement. Phase 1 of Collaboration between Biofrontera and Maruho completed Leverkusen, Germany - July 10, 2018 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (Biofrontera) announced the completion of phase 1 of the collaboration wit...

Former DAVIDsTEA CEO Joins True Leaf as Director

DGAP-News: True Leaf Medicine International Ltd. / Key word(s): Change of Personnel/Market launch 10.07.2018 / 13:10 The issuer is solely responsible for the content of this announcement. Former DAVIDsTEA CEO Joins True Leaf as Director Sylvain Toutant will help guide the company's continued growth as a leading plant-forward wellness brand for people and pets VERNON, BC - July 10, 201...

Monday 9th July 2018

Zur Rose Group AG increases public bond to CHF 115 million

EQS Group-News: Zur Rose Group AG / Key word(s): Bond 09.07.2018 / 17:51 Press release NOT FOR DISTRIBUTION IN THE UNITED STATES Zur Rose Group AG increases public bond to CHF 115 million Due to strong demand, Zur Rose Group AG announces today an increase of CHF 30 million of the public bond launched on 22 June 2018, bringing the new total outstanding amount to CHF 115 million. The fin...

CO.DON AG: CO.DON signs Letter of Intent with Xintela

DGAP-News: CO.DON AG / Key word(s): Letter of Intent 09.07.2018 / 11:47 The issuer is solely responsible for the content of this announcement. CO.DON signs Letter of Intent with Xintela Teltow / Berlin, 9th of July 2018 - As announced today per adhoc CO.DON has signed a Letter of Intent with Xintela. The parties intend to co-develop a stem cell product for the treatment of osteoarthri...

CO.DON AG: CO.DON negotiates with Xintela on the establishment of a joint venture

CO.DON AG / Key word(s): Letter of Intent CO.DON AG: CO.DON negotiates with Xintela on the establishment of a joint venture 09-Jul-2018 / 08:30 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. CO.DON AG (ISIN: DE...

Friday 6th July 2018

Biofrontera AG: Biofrontera AG will be completing a voluntary review of the February 2018 share issuance

DGAP-News: Biofrontera AG / Key word(s): Miscellaneous 06.07.2018 / 15:19 The issuer is solely responsible for the content of this announcement. Biofrontera AG will be completing a voluntary review of the February 2018 share issuance Leverkusen, Germany - 06 July 2018 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) ("Biofrontera" or the "Company"), an international...

SYGNIS AG: SYGNIS AG announces outcome of Annual General Meeting 2018 (news with additional features)

DGAP-News: SYGNIS AG / Key word(s): AGM/EGM 06.07.2018 / 13:30 The issuer is solely responsible for the content of this announcement. PRESS RELEASE 06 July 2018 / SYGNIS AG announces outcome of Annual General Meeting 2018 Shareholders approve all management proposals Heidelberg, Germany and Cambridge, UK, 06 July 2018 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)...

UMS United Medical Systems International AG i.L.: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

UMS United Medical Systems International AG / Preliminary announcement on the disclosure of financial statements 06.07.2018 / 10:00 Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. -----...

Thursday 5th July 2018

Biofrontera AG: Sales revenue for Ameluz(R) doubled for the six-month period ended June 30, 2018

DGAP-News: Biofrontera AG / Key word(s): Market Report/Half Year Results 05.07.2018 / 17:45 The issuer is solely responsible for the content of this announcement. Sales revenue for Ameluz(R) doubled for the six-month period ended June 30, 2018 Leverkusen, Germany, July 5, 2018 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) ("Biofrontera" or the "Company"), an internatio...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks